Check Before You Invest : Mahamaya Lifesciences Ltd

Q: Which industry/sub-sector does Mahamaya Lifesciences Ltd belong to?

Mahamaya Lifesciences Ltd belongs to the Chemicals & Fertilizers sector, operating specifically within the Pesticides & Agrochemicals segment.

Q: Is Mahamaya Lifesciences Ltd a good quality company?

Mahamaya Lifesciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Mahamaya Lifesciences Ltd undervalued or overvalued?

Mahamaya Lifesciences Ltd appears Somewhat overvalued, as its key valuation ratios are higher than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: 31.58, Historic Median: 31.58. Price to Book, Current: 3.55, Historic Median: 3.57. Price to Sales, Current: 1.53, Historic Median: 1.53. EV to EBITDA, Current: 17.53, Historic Median: 17.53

Q: Is Mahamaya Lifesciences Ltd a good buy now?

Mahamaya Lifesciences Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd revenue growth is 63.5% for FY-2025, which is above its 3-year CAGR of 43.22%, indicating faster growth.

Q: Gross Profit margin of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 7.2% for FY-2025, which is above its 3-year median of 5.5%, indicating increasing margins.

Q: Operating Profit Margin of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 8.77% for FY-2025, which is in line with its 3-year median of 8.45% indicating stable margins.

Q: Net Profit Margin of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Net Profit Margin is 4.85% for FY-2025, is above its 3-year median of 3.39%, indicating increasing margins. Profitability Metrics. Gross Profit Margin (%), Current: 7.2, Historic Median: 5.5. Operating Profit Margin (%), Current: 8.77, Historic Median: 8.45. Net Profit Margin (%), Current: 4.85, Historic Median: 3.39

Q: Return on Asset of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Return on Asset is 8.51%, which is above its 3-year historical median of 5.74%, indicating improved asset utilization efficiency.

Q: Return on capital employed (ROCE) of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Return on capital employed is 26% for FY-2025, which is above its 3-year historical median of 21.77%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Check Before You Invest : Mahamaya Lifesciences Ltd

Snapshot

Q.1 Which industry/sub-sector does Mahamaya Lifesciences Ltd belong to?

Mahamaya Lifesciences Ltd belongs to the Chemicals & Fertilizers sector, operating specifically within the Pesticides & Agrochemicals segment.

Q.2 Is Mahamaya Lifesciences Ltd a good quality company?

Mahamaya Lifesciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Mahamaya Lifesciences Ltd undervalued or overvalued?

Mahamaya Lifesciences Ltd appears Somewhat overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	3-year Historic Median
Price to Earnings	31.58	31.58
Price to Book	3.55	3.57
Price to Sales	1.53	1.53
EV to EBITDA	17.53	17.53

Q.4 Is Mahamaya Lifesciences Ltd a good buy now?

Mahamaya Lifesciences Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd revenue growth is 63.5% for FY-2025, which is above its 3-year CAGR of 43.22%, indicating faster growth.

Q.2 Gross Profit margin of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 7.2% for FY-2025, which is above its 3-year median of 5.5%, indicating increasing margins.

Q.3 Operating Profit Margin of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 8.77% for FY-2025, which is in line with its 3-year median of 8.45% indicating stable margins.

Q.4 Net Profit Margin of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Net Profit Margin is 4.85% for FY-2025, is above its 3-year median of 3.39%, indicating increasing margins.

	Current Level	3-year Historic Median
Gross Profit Margin (%)	7.2	5.5
Operating Profit Margin (%)	8.77	8.45
Net Profit Margin (%)	4.85	3.39

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Return on Asset is 8.51%, which is above its 3-year historical median of 5.74%, indicating improved asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Return on capital employed is 26% for FY-2025, which is above its 3-year historical median of 21.77%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q.7 Return on Equity (ROE) of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Return on equity is 34.17% for FY-2025, which is above its 3-year historical median of 24.37%, indicating the business is making better use of its shareholders capital.

Q.8 Cash conversion cycle of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Cash conversion cycle is 100 days, above its 3-year historical median of 80 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	3-year Historic Median
Asset Turnover (x)	1.75	1.75
ROE (%)	34.17	24.37
ROCE (%)	26	21.77
Cash Conversion Cycle	100 days	80 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Debt-to-Equity ratio is 1.16, which is above the industry average of 0.27, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Mahamaya Lifesciences Ltd?

Mahamaya Lifesciences Ltd Debt to cash flow from operations is -17.33, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Mahamaya Lifesciences Ltd?

Q.1 Promoter shareholding and pledge status of Mahamaya Lifesciences Ltd?

Promoters hold 56.35% of the Mahamaya Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Mahamaya Lifesciences Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Mahamaya Lifesciences Ltd vs industry peers?

Mahamaya Lifesciences Ltd revenue CAGR is 43.22%, compared to the industry median CAGR of 4.98%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	3-year Industry Median
Revenue Growth (%)	63.5	5
Gross Profit Growth (%)	111.1	3.5
Operating Profit Growth (%)	64.3	2.5
Net Profit Growth (%)	160	3.4

Operating Efficiency

	Current Level	3-year Industry Median
Asset Turnover (x)	1.75	1.14
ROE (%)	34.17	12.27
ROCE (%)	26	14.12
Cash Conversion Cycle (days)	100.37	98

Valuation & price assessment

Q.1 Stock return of Mahamaya Lifesciences Ltd over the last decade?

Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	-	-	-	-

Q.2 Valuation ratios of Mahamaya Lifesciences Ltd vs historical?

The current P/E ratio of 31.58 is in line with than its historical median of 31.58, indicating that the stock is trading near its historical average valuation.

Q.3 How do the current valuation ratios compare with 3-year historical median and industry numbers?

Valuation Ratios	Current	3-year Historic Median	3-year Industry Median
Price to Earnings	31.58	31.58	28.02
Price to Book	3.55	3.57	2.65
Price to Sales	1.53	1.53	1.48
EV to EBITDA	17.53	17.53	14.08

Check more companies

10. Insecticides India

Check trending companies

1. Piramal Pharma Ltd.

2. JB Chemicals & Pharmaceuticals Ltd.

3. Cohance Lifesciences Ltd.

4. Anant Raj Ltd.

5. Yes Bank Ltd.

Check Before You Invest : Mahamaya Lifesciences Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.